सारांश
Health 15 जून
Endocrine Society meeting features studies on diet and medication effects
Eliminating sucrose from a low-fat diet worsened glucose tolerance and altered the gut microbiome in mice over 16 weeks according to results presented on Saturday June 13 2026 at ENDO 2026 the Endocrine Society annual meeting in Chicago. Adults with obesity who began taking GLP-1 receptor agonist medications showed declines in Fitbit-measured physical activity after starting treatment according to a retrospective study presented Saturday at ENDO 2026 the Endocrine Society annual meeting in Chicago. The presentations occurred on the same day during the annual gathering of endocrinology experts where data on dietary modifications in animal models and medication influences on human activity patterns were shared with attendees. Researchers highlighted observations from controlled experiments lasting sixteen weeks in mice alongside retrospective analysis of device-tracked movements in treated patients. These reports formed part of the scientific program at the event held in Chicago emphasizing metabolic health topics without additional details released beyond the initial findings.
- Mice on sucrose-free low-fat diet showed impaired glucose control and gut inflammation, researchers report
- Study: Physical activity fell after some patients with obesity started GLP-1 drugs
Former Senate Majority Leader Mitch McConnell admitted to hospital after incident
Former Senate Majority Leader Mitch McConnell was admitted to a hospital on Sunday following an unknown medical incident. His spokesman said the 84-year-old Kentucky Republican is receiving excellent care. Details about his condition remain limited. The admission occurred recently with statements from his office confirming ongoing medical attention but providing no further specifics on the nature of the incident or expected duration of stay. Reports indicate that the event prompted immediate hospitalization while emphasizing the quality of care being provided to the longtime senator from Kentucky. Information released publicly has been minimal leaving many aspects of the situation undisclosed at this time.
Medical secretaries report deficiencies in new journal system at Falu Lasarett
Medical secretaries at Falu Lasarett women clinic have submitted a report on deficiencies in the new journal system Cosmic. The submission highlights problems encountered by staff in the women clinic following implementation of the updated records platform. Staff members compiled documentation detailing various shortcomings associated with the Cosmic system at the Swedish hospital facility. This action represents an official channel for addressing workflow challenges introduced by the transition to the new journal software. The report centers on practical impacts experienced during daily operations in the specified clinic department.
Figaro journalist investigates multilevel marketing firm selling supplements
A Figaro journalist spent nearly two months as a seller at Wake Up a multilevel marketing firm promoting phycocyanine-based supplements. The extended period allowed direct observation of sales practices and operations within the organization. The investigation involved the journalist assuming a role in product distribution to gather firsthand accounts of the multilevel structure and supplement promotion methods. Coverage focused on the experience of working inside the firm known for its emphasis on phycocyanine products derived from specific sources. The resulting report provides insights gained over the course of the nearly eight-week immersion in the sales environment.
France begins social security coverage for Mounjaro and Wegovy medications
Starting this Monday social security covers Mounjaro and Wegovy for patients with severe obesity or diabetes. It is a first in Europe. The policy change introduces reimbursement for these medications under the national health system for qualifying individuals. Implementation begins on the specified day marking an initial step among European countries to provide such coverage. Eligible patients include those diagnosed with severe obesity or diabetes who meet established criteria for the treatments. This development represents a shift in access to the GLP-1 related therapies through public funding mechanisms in France.